Skip to main content
SpringerLink
Log in

Systemic therapy of hepatocellular carcinoma: Are we making progress?

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer deaths. Surgical resection, with or without transplantation, can result in long-term survival. However, surgery can only be performed in about 15% of patients with HCC and the 5-year survival rate is only approximately 33%–50% after potentially curative resection. Percutaneous ethanol injection, radiofrequency ablation, and transarterial chemoembolization are invasive techniques that have shown efficacy in reducing tumor bulk. Similarly, systemic chemotherapy may induce tumor responses, but a survival benefit has not been clearly demonstrated. In addition, the lack of efficacy of antiandrogens, tamoxifen, and single-agent interferon has now been confirmed.

Sorafenib is a multikinase inhibitor with antiangiogenic, proapoptotic, and Raf kinase inhibitory activity. In a large, multicenter, randomized, phase 3 trial there was a significant improvement in both time to disease progression and overall survival with sorafenib compared with placebo. Sorafenib is the first agent to demonstrate a consistent improvement in overall survival for patients with advanced HCC. Further studies are required to determine the role of other molecular-targeted therapies, either alone or in combination with sorafenib in patients with advanced HCC. Further studies are also required to determine the role of sorafenib in combination with locoregional therapies (eg, transarterial chemoembolization), and the role of sorafenib as adjuvant therapy following surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer. 2001;94:153–156.

    Article  PubMed  CAS  Google Scholar 

  2. Johnson PJ. Liver. In: Price P, Sikora K, eds. Treatment of Cancer. 4th edition. London: Arnold Publishers; 2002:535–565.

    Google Scholar 

  3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750.

    Article  PubMed  CAS  Google Scholar 

  4. Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan that predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A. 2002;99:15584–15589.

    Article  PubMed  CAS  Google Scholar 

  5. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–472.

    Article  PubMed  CAS  Google Scholar 

  6. Bosch X, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271–285.

    Article  PubMed  CAS  Google Scholar 

  7. Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: a prospective study. Gastroenterology. 1986;90:263–267.

    PubMed  CAS  Google Scholar 

  8. Sun Z, Lu P, Gail MH, et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable aflatoxin metabolite M1. Hepatology. 1999;30:379–383.

    Article  PubMed  CAS  Google Scholar 

  9. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis virus: a prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129–1133.

    Article  PubMed  CAS  Google Scholar 

  10. Margolis HS, Alter MJ, Hadler SC. Viral hepatitis. In: Evans AS, Kaslow RA, eds. Viral Infection in Humans. 4th edition. New York: Plenim Medical Book Co.; 1997:363–418.

    Google Scholar 

  11. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336:1855–1859.

    Article  PubMed  CAS  Google Scholar 

  12. Chang MH, Shau WY, Chen CJ, et al. The Taiwan Childhood Hepatoma Study Group. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 2000;284:3040–3042.

    Article  PubMed  CAS  Google Scholar 

  13. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797–1801.

    Article  PubMed  CAS  Google Scholar 

  14. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in non-cirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256–1262.

    PubMed  CAS  Google Scholar 

  15. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavarin compared with interferon alfa-2b plus ribavarin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965.

    Article  PubMed  CAS  Google Scholar 

  16. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917.

    Article  PubMed  Google Scholar 

  17. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–524.

    Article  PubMed  Google Scholar 

  18. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment of early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434–1440.

    Article  PubMed  CAS  Google Scholar 

  19. Bismuth H, Majno P. Hepatobiliary surgery. J Hepatol. 2000;32(suppl. 1):208–224.

    Article  PubMed  CAS  Google Scholar 

  20. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: a review of the randomized clinical trials. Lancet Oncol. 2002;3:593–603.

    Article  PubMed  Google Scholar 

  21. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med. 1996;334:1561–1567.

    Article  PubMed  CAS  Google Scholar 

  22. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet. 2000;356:784–785.

    Article  Google Scholar 

  23. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for respectable hepatocellular carcinoma: a prospective randomized trial. Lancet. 1999;353:797–801.

    Article  PubMed  CAS  Google Scholar 

  24. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.

    Article  PubMed  CAS  Google Scholar 

  25. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 1999;19:311–322.

    Article  PubMed  CAS  Google Scholar 

  26. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for heptocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–1086.

    Article  PubMed  CAS  Google Scholar 

  27. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403.

    Article  PubMed  CAS  Google Scholar 

  28. Mazzaferro V, Chun YS, Poon RTP, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008;15:1001–1007.

    Article  PubMed  Google Scholar 

  29. Lubienski A. Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation. 2005;8(suppl. 1):S113–S119.

    Article  Google Scholar 

  30. Trotter J, Wachs M, Everson G, Kam I. Adult-to-adult transplantation of the right hepatic lobe from living donor. N Engl J Med. 2002;346:1074–1082.

    Article  PubMed  Google Scholar 

  31. Cronin D, Millis M, Siegler M. Transplantation of liver grafts from living donors into adults: too much, too soon. N Engl J Med. 2001;344:1633–1637.

    Article  PubMed  Google Scholar 

  32. Okada S. Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis. 1999;19:323–328.

    Article  PubMed  CAS  Google Scholar 

  33. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology. 1995;197:101–108.

    PubMed  CAS  Google Scholar 

  34. Lencioni R, Pinto F, Armillotta N, et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol. 1997;7:514–519.

    Article  PubMed  CAS  Google Scholar 

  35. Mulier S, Mulier P, Ni Y, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg. 2002;89:1206–1222.

    Article  PubMed  CAS  Google Scholar 

  36. Lencioni R, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized controlled trial of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–240.

    Article  PubMed  Google Scholar 

  37. Hong SN, Lee SY, Choi MS, et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol. 2005;39:247–252.

    Article  PubMed  Google Scholar 

  38. Vivarelli M, Guglielmi A, Ruzzenente A, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240:102–107.

    Article  PubMed  Google Scholar 

  39. Guglielmi A, Ruzzenente A, Valdegamberi A, et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg. 2008;12:192–198.

    Article  PubMed  Google Scholar 

  40. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Gastroenterology. 1988;94:453–456.

    PubMed  CAS  Google Scholar 

  41. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990;11:181–184.

    Article  PubMed  CAS  Google Scholar 

  42. Group d’Etude et de Traitment du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995;332:1256–1261.

    Article  Google Scholar 

  43. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized controlled trial in a single institution. Hepatology. 1998;27:1578–1583.

    Article  PubMed  CAS  Google Scholar 

  44. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol. 1998;29:129–134.

    Article  PubMed  CAS  Google Scholar 

  45. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171.

    Article  PubMed  CAS  Google Scholar 

  46. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734–1739.

    Article  PubMed  Google Scholar 

  47. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442.

    Article  PubMed  CAS  Google Scholar 

  48. Ng IO, Liu CL, Fan ST, Ng M. Expression of p-glycoprotein in hepatocellular carcinoma: a determinant of chemotherapy response. Am J Clin Pathol. 2000;113:355–363.

    Article  PubMed  CAS  Google Scholar 

  49. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988;62:479–483.

    Article  PubMed  CAS  Google Scholar 

  50. Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Invest Drugs. 2004;13:1555–1568.

    Article  CAS  Google Scholar 

  51. Jhawer M, Rosen L, Dancey J, et al. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG337] in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2007;25:85–94.

    Article  PubMed  CAS  Google Scholar 

  52. Stuart K, Tessitore J, Rudy J, Clendennin N, Johnston A. A phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma. Cancer. 1999;86:410–414.

    Article  PubMed  CAS  Google Scholar 

  53. Mok TS, Leung TW, Lee SD, et al. A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 1999;44:307–311.

    Article  PubMed  CAS  Google Scholar 

  54. Gish RG, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007;25:3069–3075.

    Article  PubMed  CAS  Google Scholar 

  55. Posey J, Johnson T, Mok M, et al. Results of a phase 2/3 open-label, randomized trial of T138067 versus doxorubicin (DOX) in chemotherapy-naïve, unresectable hepatocellular carcinoma. J Clin Oncol. 2005;23:4035. Abstract.

    Google Scholar 

  56. Boyer SH, Sun Z, Jiang H, et al. Synthesis and characterization of a novel livertargeted prodrug of cytosine-1-beta-Darabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J Med Chem. 2006;49:7711–7720.

    Article  PubMed  CAS  Google Scholar 

  57. Ma B, Forbes W, Venook AP, et al. A phase I/II study to assess the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) infusion of MB07133 in subjects with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2006;24:2054. Abstract.

    Article  CAS  Google Scholar 

  58. Leung TW, Patt Z, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res. 1999;5:1676–1681.

    PubMed  CAS  Google Scholar 

  59. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:1532–1538.

    PubMed  CAS  Google Scholar 

  60. Boix L, Bruix J, Castells A, et al. Sex hormone receptors in hepatocellular carcinoma: is there a rationale for hormonal treatment? J Hepatol. 1993;17:187–191.

    Article  PubMed  CAS  Google Scholar 

  61. Jiang SY, Shyu RY, Yeh MY, Jordan VC. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol. 1995;23:712–719.

    Article  PubMed  CAS  Google Scholar 

  62. Farinati F, Salvagnini M, de Maria N, et al. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol. 1990;11:297–301.

    Article  PubMed  CAS  Google Scholar 

  63. Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol. 1994;26:66–68.

    PubMed  CAS  Google Scholar 

  64. Martínez Cerezo FJ, Tomás A, Donoso L, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol. 1994;20:702–706.

    Article  PubMed  Google Scholar 

  65. Castells A, Bruix J, Brú C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology. 1995;109:917–922.

    Article  PubMed  CAS  Google Scholar 

  66. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology. 1995;21:1535–1542.

    PubMed  CAS  Google Scholar 

  67. CLIP Group. Tamoxifen in treatment of hepatocellular carcinoma: a randomized controlled trial. Lancet. 1998;352:17–20.

    Article  Google Scholar 

  68. Riestra S, Rodriguez M, Delgado M, et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol. 1998;26:200–203.

    Article  PubMed  CAS  Google Scholar 

  69. Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol. 2000;95:218–222.

    Article  PubMed  CAS  Google Scholar 

  70. Chow PK, Tai BC, Tan CK, et al. High dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology. 2002;36:1221–1226.

    Article  PubMed  CAS  Google Scholar 

  71. Villa E, Ferretti I, Grottola A, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer. 2001;84:881–885.

    Article  PubMed  CAS  Google Scholar 

  72. Grimaldi C, Bleiberg H, Gay F, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol. 1998;16:411–417.

    PubMed  CAS  Google Scholar 

  73. Reubi JC, Zimmermann A, Jonas S, et al. Regulatory peptide receptors in human hepatocellular carcinoma. Gut. 1999;45:766–774.

    Article  PubMed  CAS  Google Scholar 

  74. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836–846.

    Article  PubMed  CAS  Google Scholar 

  75. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334:246–254.

    Article  PubMed  CAS  Google Scholar 

  76. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut. 1998;42:442–447.

    PubMed  CAS  Google Scholar 

  77. Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. 2002;36:687–691.

    Article  PubMed  CAS  Google Scholar 

  78. Becker G, Allgaier HP, Olschewski M, Zähringer A, Blum HE. HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology. 2007;45:9–15.

    Article  PubMed  CAS  Google Scholar 

  79. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol. 1984;2:336–352.

    PubMed  CAS  Google Scholar 

  80. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology. 1993;17:389–394.

    Article  PubMed  CAS  Google Scholar 

  81. Sachs E, Di Bisceglie AM, Dusheiko GM, et al. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study. Br J Cancer. 1985;52:105–109.

    PubMed  CAS  Google Scholar 

  82. The Gastrointestinal Tumor Study Group. A prospective trial of recombinant human interferon alpha 2b in previously untreated patients with hepatocellular carcinoma. Cancer. 1990;66:135–139.

    Article  Google Scholar 

  83. Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000;31:54–58.

    Article  PubMed  CAS  Google Scholar 

  84. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor — a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228–232.

    Article  PubMed  CAS  Google Scholar 

  85. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.

    Article  PubMed  CAS  Google Scholar 

  86. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109.

    Article  PubMed  CAS  Google Scholar 

  87. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561–574.

    Article  PubMed  CAS  Google Scholar 

  88. Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 1998;27:951–958.

    Article  PubMed  CAS  Google Scholar 

  89. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007;27:55–76.

    Article  PubMed  CAS  Google Scholar 

  90. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006;130:1117–1128.

    Article  PubMed  CAS  Google Scholar 

  91. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol. 2004;41:864–880.

    Article  PubMed  Google Scholar 

  92. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851–11858.

    Article  PubMed  CAS  Google Scholar 

  93. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293–4300.

    Article  PubMed  CAS  Google Scholar 

  94. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.

    Article  PubMed  CAS  Google Scholar 

  95. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216.

    Article  PubMed  CAS  Google Scholar 

  96. Yount S, Cella D, Webster K, et al. Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index. J Pain Symptom Manage. 2002;24:32–44.

    Article  PubMed  Google Scholar 

  97. Cheng A, Kang Y, Chen Z, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol. 2008;26:4509. Abstract.

    Article  Google Scholar 

  98. Abou-Alfa GK, Amadori D, Santoro A, et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol. 2008;26:4518. Abstract.

    Article  Google Scholar 

  99. Abou Alfa GK, Johnson P, Knox J, et al. Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Eur J Cancer Suppl. 2007;5:3500. Abstract.

    Google Scholar 

  100. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2005;23:6657–6663.

    Article  PubMed  CAS  Google Scholar 

  101. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007;110:1059–1067.

    Article  PubMed  CAS  Google Scholar 

  102. O’Dwyer PJ, Giantonio BJ, Levy DE, Kauh JS, Fitzgerald DB, Benson AB3rd. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group’s Study E1203. J Clin Oncol. 2006;24:4143. Abstract.

    Article  CAS  Google Scholar 

  103. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992–2998.

    Article  PubMed  CAS  Google Scholar 

  104. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:1898–1903.

    Article  PubMed  CAS  Google Scholar 

  105. Faivre SJ, Raymond E, Douillard J, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2007;25:3546. Abstract.

    Google Scholar 

  106. Zhu AX, Sahani DV, di Tomaso E, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2007;25:4637. Abstract.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Beatson West of Scotland Cancer Centre, Glasgow, UK

    Patricia Roxburgh & T. R. Jeffry Evans

  2. University of Glasgow, Cancer Research UK Beatson Laboratories, Glasgow, UK

    T. R. Jeffry Evans

  3. University of Glasgow, Cancer Research UK Beatson Laboratories, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK

    T. R. Jeffry Evans

Authors
  1. Patricia Roxburgh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. R. Jeffry Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. R. Jeffry Evans.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roxburgh, P., Evans, T.R.J. Systemic therapy of hepatocellular carcinoma: Are we making progress?. Adv Therapy 25, 1089–1104 (2008). https://doi.org/10.1007/s12325-008-0113-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-008-0113-z

Keywords

Search

Navigation